(Q34631795)

3 August 2017

1 reference

title

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab (English)

1 reference

3 August 2017

1 reference

A J Davies

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

26

1 reference

3 August 2017

issue

25

1 reference

3 August 2017

page(s)

3614-3628

1 reference

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Radioimmunotherapy of non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Histological transformation of non-hodgkin's lymphoma.A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Radioimmunotherapy--hot new treatment for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210378

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210378

1 reference

Dimensions Publication ID

3 August 2017

1050456992

0 references

1 reference